LOGIN  |  REGISTER
Astria Therapeutics
Astria Therapeutics

Phibro Animal Health to Participate in Stifel Dental and Animal Health (Jaws & Paws) Conference

May 20, 2024 | Last Trade: US$23.09 0.24 1.05

TEANECK, N.J. / May 20, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference.

Chief Financial Officer, Glenn David along with Larry Miller, Chief Operating Officer and EVP Corporate Strategy, Daniel Bendheim will address financial analysts and investors on Wednesday, May 29, 2024, at 10:20 AM ET at the St. Regis New York.

The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company’s website.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.

Our filings with the Securities and Exchange Commission are available online at www.sec.gov, www.pahc.com or on request from the company.

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB